Centpropazine

In this article we will explore everything related to Centpropazine, a topic of great relevance today that has generated different opinions and points of view. Centpropazine has been present throughout history, impacting various areas of society and culture. We will learn about its origins, its evolution over time and its impact on people's lives. We will analyze the different aspects that revolve around Centpropazine, from its implications on the economy to its influence on the way we relate to each other. Through this article, we will delve into the fascinating world of Centpropazine and discover its importance in the current context.

Centpropazine
Clinical data
Other namesCPZ; CTZ
Routes of
administration		Oral[1]
Identifiers
  • 1-phenyl]propan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H28N2O3
Molar mass368.477 g·mol−1
3D model (JSmol)
  • CCC(=O)C1=CC=C(C=C1)OCC(CN2CCN(CC2)C3=CC=CC=C3)O
  • InChI=1S/C22H28N2O3/c1-2-22(26)18-8-10-21(11-9-18)27-17-20(25)16-23-12-14-24(15-13-23)19-6-4-3-5-7-19/h3-11,20,25H,2,12-17H2,1H3
  • Key:ZQPXSRTZFYHSFB-UHFFFAOYSA-N

Centpropazine (CPZ, CTZ) is an experimental antidepressant which was under development for the treatment major depressive disorder in India but was never marketed.[1][2][3] It is described as having imipramine-like clinical effects, reversing reserpine-induced effects in animals, and potentiating amphetamine-induced effects in animals.[3] The mechanism of action of centpropazine is unknown.[4] The drug reached phase 3 clinical trials prior to the discontinuation of its development.[1] It was first described in the scientific literature by 1980.[3][5]

References

  1. ^ a b c "Centpropazine". AdisInsight. Springer Nature Switzerland AG. 10 December 2013. Retrieved 27 September 2024.
  2. ^ Avasthi A, Grover S, Aggarwal M (January 2010). "Research on antidepressants in India". Indian Journal of Psychiatry. 52 (Suppl 1): S341 – S354. doi:10.4103/0019-5545.69263. PMC 3146188. PMID 21836704.
  3. ^ a b c Kaiser C, Bondinell WE (1981). "Chapter 1. Antidepressants". Annual Reports in Medicinal Chemistry. Vol. 16. Elsevier. p. 1–10. doi:10.1016/s0065-7743(08)61268-3. ISBN 978-0-12-040516-9. ISSN 0065-7743.
  4. ^ shrafuzzaman M, Ji SH, Ahn H, Chung HW, Choi D, Park JJ, Go M, Pyo JI, Shafioul AS, Lee DH, Chi SG (29 March 2023). "Identification of 1-phenoxy-3-(piperazin-1-yl)propan-2-ol derivatives as novel triple reuptake inhibitors". Bulletin of the Korean Chemical Society. 44 (7). Wiley: 596–599. doi:10.1002/bkcs.12693. ISSN 1229-5949.
  5. ^ Singh H, Chawla AS, Kapoor VK (1985). "Medicinal chemistry research in India". Progress in Medicinal Chemistry. 22: 243–266. doi:10.1016/s0079-6468(08)70232-7. ISBN 978-0-444-80668-0. PMID 2873624.